Navigation Links
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
Date:4/14/2008

and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
3. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
4. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
5. Cephalon General Counsel John E. Osborn to Resign Position
6. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
7. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
8. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
9. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
10. Cephalon Submits Supplemental New Drug Application for FENTORA
11. Cephalon Announces Strong Third Quarter Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...,, SEATTLE,Nov.23/PRNewswire/--ImmuneDesignC or...nedIDCasExecutiveChairman.Dr.Carterhasasuccessfult...asthef or merChiefExecutiveOfficeratZymoGenetics,i...k,Copenhagen,Denmark. ,, (Photo: http://www.new...StevenReed,IDC,sfounderandChiefExecutiveOfficercom...
(Date:11/20/2009)..., , , , , , , , , ... , , AUDIO: , A team of scientis...iversity of Arizona, Cold Spring Harbor Laboratory... the DNA of corn. The... , , Clic... , , , , , , , ,...
(Date:11/20/2009)..., , STOCKHOLM, November 20 /PRNewswir...at the European Investment Fund (EIF) has entered ...he co-investment fund will be,managed by Karolinsk...portfolio of early-stage pharmaceutical and medica...6.7 M Euros in the co-investment fund. The agreeme...
(Date:11/19/2009)..., , COPENHAGEN, Nov. 19 Danish...bicon cellulosic ethanol plant in Kalundborg, Denm...e of the world,s first and largest 2nd generation ...cellerase enzymes are used in the plant,s innovati... a Division of Danisco, was the first to market wi...
Breaking Biology Technology:Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2
...NGELES, March 17 Signalife, Inc. (Amex:,SGN - New...veral formal,purchase and financial commitments wi...logy licenses, devices and services. These commitm..., other parts of Asia and Europe,as well as domest...d CEO, stated: "I anticipate,closing these transac...
...OUIS, March 17 (Nasdaq: SIAL ) -- Sigma-,Aldrich...ng its 2008 Annual,Business Review on Wednesday, M...y Center located at 2909 Laclede, St. Louis, Mo. 6...onclude by 12:30 p.m. CDT,and will also be webcast...ma-aldrich.com ., About Sigma-Aldrich: Sigma-Aldr...
...xpands Development and Support of National Electro...System, EL SEGUNDO, Calif., March 17 Computer,Sc...hat it has been awarded a,task order from the Cent...ntinue developing and supporting the National Elec...stem (NBS). The system helps the CDC,manage and en...
Other Biology Technology:Signalife Sees Accretive Purchase and Financial Commitments 2CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order 2
(Date:11/23/2009)...in German . , A bit of imagination on the p...ing. It could help to add data from areas where th...t do so constructively. In order to infer missing ... just imagination, physicists at the Max Planck In...of spatial perception called information field the...
(Date:11/23/2009)...in German . , Not just birds, but also a fe...Researchers at Princeton University in the U.S. an...adolfzell, Germany studied the migratory behaviour...ed "Vespertilionidae" with the help of mathematica...short as well as long distances of various kinds o...
(Date:11/22/2009)...sed prenatally to tobacco smoke and during childho... according to research done at Cincinnati Children...s that up to 35 percent of ADHD cases in children ...liminating both of these environmental exposures. ..., "Tobacco and lead exposure each have their own...
Breaking Biology News(10 mins):Visual assistance for cosmic blind spots 2Visual assistance for cosmic blind spots 3Visual assistance for cosmic blind spots 4We're off then: The evolution of bat migration 2Exposure to lead, tobacco smoke raises risk of ADHD 2AFFiRiS AG 3A Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimers Vaccine Candidate AD02 into Clinical Phase II Testing 14915 1AFFiRiS AG 3A Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimers Vaccine Candidate AD02 into Clinical Phase II Testing 14915 2AFFiRiS AG 3A Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimers Vaccine Candidate AD02 into Clinical Phase II Testing 14915 3Morehead Presents Webinar on 26quot 3BHow Physician Attitudes Impact Hospital Goals 26quot 3B 61678 1Morehead Presents Webinar on 26quot 3BHow Physician Attitudes Impact Hospital Goals 26quot 3B 61678 2AAHSA Statement on Senate Health Reform Bill 61676 1AAHSA Statement on Senate Health Reform Bill 61676 2
...mplications for understanding kidney disorders, ge...hiladelphia have identified a second gene that giv...tal disease that affects multiple organs. The Chil...st gene associated with this disease. , The resea...e linked to kidney abnormalities in patients and f...
...sed by arterial blockages related to diabetes, smo...re occurring at an alarming rate. Yet physicians m...may be preventable, according to the International...isfiguring and life-threatening, but are more dang...hich is the reestablishment of blood supply. Diabe...
...hed the findings of a team of scientists at the no... provides a whole genome analysis of the protein k...sm known as Dictyostelium. , Led by Dr. Janet Sm... evolution of kinases, which are enzymes involved ...% of human genes code for protein kinases, and mut...
Other Biology News:Gene discovery may shed light on kidney disease 2Epidemic of unneeded amputations 2Scientists elucidate the kinome of key model organism 2
CD14 MicroBeads, non-human primate from Miltenyi Biotec
...orm, 220 V, is used for agitation and mixing appli...tures, staining and destaining of gels and blots, ...riable speed control (8-40 rpm) and can handle a m... two 29 x 21 cm platforms covered with nonslip rub...
Mouse Anti-Human DCAMKL2 Monoclonal Antibody, Unconjugated, Clone 2A5 from Novus Biologicals
CD43 MicroBeads, rat from Miltenyi Biotec
Biology Products: